{
    "clinical_study": {
        "@rank": "120872", 
        "arm_group": [
            {
                "arm_group_label": "Low dose Sabin-IPV", 
                "arm_group_type": "Experimental", 
                "description": "Intramuscular injection of 0.5 ml of Inactivated Poliomyelitis Vaccine containing 5, 8, 16 D-antigen units respectively of Sabin-1,-2 and -3 per dose.\nInfants receive three vaccinations with an interval of 8 weeks between doses."
            }, 
            {
                "arm_group_label": "Low dose adjuvanted Sabin-IPV", 
                "arm_group_type": "Experimental", 
                "description": "Intramuscular injection of 0.5 ml of Inactivated Poliomyelitis Vaccine containing 2.5, 4, 8 D-antigen units respectively of Sabin-1,-2 and -3 per dose adjuvanted with 0.5 mg aluminium hydroxide.\nInfants receive three vaccinations with an interval of 8 weeks between doses."
            }, 
            {
                "arm_group_label": "Middle dose Sabin-IPV", 
                "arm_group_type": "Experimental", 
                "description": "Intramuscular injection of 0.5 ml of Inactivated Poliomyelitis Vaccine containing 10, 16, 32 D-antigen units respectively of Sabin-1,-2 and -3 per dose.\nInfants receive three vaccinations with an interval of 8 weeks between doses."
            }, 
            {
                "arm_group_label": "Middle dose adjuvanted Sabin-IPV", 
                "arm_group_type": "Experimental", 
                "description": "Intramuscular injection of 0.5 ml of Inactivated Poliomyelitis Vaccine containing 5, 8, 16 D-antigen units respectively of Sabin-1,-2 and -3 per dose adjuvanted with 0.5 mg aluminium hydroxide.\nInfants receive three vaccinations with an interval of 8 weeks between doses."
            }, 
            {
                "arm_group_label": "High dose Sabin-IPV", 
                "arm_group_type": "Experimental", 
                "description": "Intramuscular injection of 0.5 ml of Inactivated Poliomyelitis Vaccine containing 20, 32, 64 D-antigen units respectively of Sabin-1,-2 and -3 per dose.\nInfants receive three vaccinations with an interval of 8 weeks between doses."
            }, 
            {
                "arm_group_label": "High dose adjuvanted Sabin-IPV", 
                "arm_group_type": "Experimental", 
                "description": "Intramuscular injection of 0.5 ml of Inactivated Poliomyelitis Vaccine containing 10, 16, 32 D-antigen units respectively of Sabin-1,-2 and -3 per dose adjuvanted with 0.5 mg aluminium hydroxide.\nInfants receive three vaccinations with an interval of 8 weeks between doses."
            }, 
            {
                "arm_group_label": "Conventional IPV", 
                "arm_group_type": "Active Comparator", 
                "description": "Intramuscular injection of 0.5 ml of Inactivated Poliomyelitis Vaccine containing 40, 8, and 32 D-antigen units respectively of Mahoney, MEF-1 and Saukett poliovirus per dose.\nInfants receive three injections with an interval of 8 weeks between doses."
            }
        ], 
        "brief_summary": {
            "textblock": "A new inactivated polio vaccine based on attenuated poliovirus strains was developed to\n      transfer the technology to manufacturers in low- and middle-income countries. This vaccine\n      was produced in different dosages and in different formulations. In healthy adults the\n      safety of the highest dose was comparable to that of the existing inactivated polio vaccine.\n      The purpose of this trial is to determine the safety of the different dosages and\n      formulations of the vaccine in infants. The second goal of this study is to analyse the\n      immune response after three doses in infants."
        }, 
        "brief_title": "Safety and Immunogenicity of a New Inactivated Poliovirus Vaccine in Infants", 
        "completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "condition": "Poliomyelitis", 
        "condition_browse": {
            "mesh_term": "Poliomyelitis"
        }, 
        "detailed_description": {
            "textblock": "The goal of this study is to assess the safety and immunogenicity of Sabin-IPV and\n      adjuvanted Sabin-IPV produced with the production process set up for technology transfer by\n      the National Institute for Public Health and the Environment (RIVM, formerly the Netherlands\n      Vaccine Institute (NVI).\n\n        -  The primary objective is to evaluate safety (local and systemic reactions) of\n           intramuscular injection with Sabin-IPV and adjuvanted Sabin-IPV in healthy infants.\n\n        -  The secondary objective is to evaluate immunogenicity of three doses Sabin-IPV and\n           adjuvanted Sabin-IPV in infants."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age 8 weeks (56-63 days) at the time of first vaccination\n\n          -  Infants in good general health, eligible to be vaccinated according to the Polish\n             national vaccination program. The same health criteria apply as used in well-baby\n             clinics when a child receives a vaccination, e.g. also children with a small increase\n             in temperature (< 38.5\u00b0 C) or with a common cold (runny nose etc) are seen as\n             children with normal health.\n\n          -  The parent(s)/legally representative(s) have to be willing and able to allow their\n             child to participate in the trial according to the described procedures\n\n          -  Presence of a signed informed consent in which the parent(s)/legally\n             representative(s) have given written informed consent after receiving oral and\n             written information (signature from one parent in case of single-parent family).\n\n        Exclusion Criteria:\n\n          -  Any IPV or OPV dose\n\n          -  Known or suspected allergy against any of the vaccine components\n\n          -  History of unusual or severe reactions to any previous vaccination administration of\n             plasma (including immunoglobulins) or blood products prior and during the study\n\n          -  Any vaccination less than 14 days before or after each vaccination with the IMP\n\n          -  History of any neurological disorder including epilepsy or febrile seizures\n\n          -  Any infectious disease at the time of screening and/or inclusion that might interfere\n             with the results of the study\n\n          -  Present evidence of serious disease(s) demanding immunosuppressive medical treatment,\n             like cytostatics and prednisolones, that might interfere with the results of the\n             study\n\n          -  Any known or suspected primary or secondary immunodeficiency\n\n          -  Communication problems interfering in the study realization according to the judgment\n             of the investigator\n\n          -  Bleeding disorders and use of anticoagulants\n\n          -  Premature birth (<37 weeks)\n\n          -  Participation in another clinical trial"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "63 Days", 
            "minimum_age": "56 Days"
        }, 
        "enrollment": {
            "#text": "140", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 16, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01709071", 
            "org_study_id": "NVI-256B", 
            "secondary_id": "2011-003792-11"
        }, 
        "intervention": [
            {
                "arm_group_label": "Conventional IPV", 
                "intervention_name": "IPV", 
                "intervention_type": "Drug", 
                "other_name": [
                    "IPV (NVI)", 
                    "Inactivated poliomyelitis vaccine", 
                    "Inactivated poliovirus vaccine", 
                    "Inactivated polio vaccine"
                ]
            }, 
            {
                "arm_group_label": "Low dose Sabin-IPV", 
                "intervention_name": "Low dose Sabin-IPV", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Low dose adjuvanted Sabin-IPV", 
                "intervention_name": "Low dose adjuvanted Sabin-IPV", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Middle dose Sabin-IPV", 
                "intervention_name": "Middle dose Sabin-IPV", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Middle dose adjuvanted Sabin-IPV", 
                "intervention_name": "Middle dose adjuvanted Sabin-IPV", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "High dose Sabin-IPV", 
                "intervention_name": "High dose Sabin-IPV", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "High dose adjuvanted Sabin-IPV", 
                "intervention_name": "High dose adjuvanted Sabin-IPV", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Vaccination", 
            "Inactivated poliomyelitis vaccine", 
            "poliomyelitis", 
            "Sabin strains"
        ], 
        "lastchanged_date": "February 20, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Bydgoszcz", 
                        "country": "Poland"
                    }, 
                    "name": "NZOZ Centrum Zdrowia \"B\u0142onie\""
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Krakow", 
                        "country": "Poland"
                    }, 
                    "name": "Szpital im. Jana Paw\u0142a II"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Krakow", 
                        "country": "Poland"
                    }, 
                    "name": "Specjalistyczna Poradnia Medyczna \"Przyl\u0105dek Zdrowia\""
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lubart\u00f3w", 
                        "country": "Poland"
                    }, 
                    "name": "Samodzielny Publiczny ZOZ"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lublin", 
                        "country": "Poland"
                    }, 
                    "name": "NZOZ Praktyka Lekarza Rodzinnego \"Eskulap\""
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Siemianowice \u015al\u0105skie", 
                        "country": "Poland"
                    }, 
                    "name": "NZLA Micha\u0142kowice Jarosz i Partnerzy Sp\u00f3\u0142ka Lekarsk"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tarn\u00f3w", 
                        "country": "Poland"
                    }, 
                    "name": "Alergo-Med Specjalistyczna Przychodnia Lekarska Sp z o.o."
                }
            }
        ], 
        "location_countries": {
            "country": "Poland"
        }, 
        "number_of_arms": "7", 
        "official_title": "Double Blind Dose - Escalation, Randomized, Controlled, Phase I-II Trial to Evaluate Safety and Immunogenicity of Three Doses of Sabin-IPV and Adjuvanted Sabin-IPV in Healthy Infants", 
        "overall_official": {
            "affiliation": "National Institute for Public Health and the Environment (RIVM)", 
            "last_name": "Pauline Verdijk, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "November 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Number of adverse reactions following vaccination", 
            "safety_issue": "Yes", 
            "time_frame": "5 days or until adverse reactions have resolved"
        }, 
        "reference": [
            {
                "PMID": "21651934", 
                "citation": "Bakker WA, Thomassen YE, van't Oever AG, Westdijk J, van Oijen MG, Sundermann LC, van't Veld P, Sleeman E, van Nimwegen FW, Hamidi A, Kersten GF, van den Heuvel N, Hendriks JT, van der Pol LA. Inactivated polio vaccine development for technology transfer using attenuated Sabin poliovirus strains to shift from Salk-IPV to Sabin-IPV. Vaccine. 2011 Sep 22;29(41):7188-96. doi: 10.1016/j.vaccine.2011.05.079. Epub 2011 Jun 7."
            }, 
            {
                "PMID": "21604984", 
                "citation": "Verdijk P, Rots NY, Bakker WA. Clinical development of a novel inactivated poliomyelitis vaccine based on attenuated Sabin poliovirus strains. Expert Rev Vaccines. 2011 May;10(5):635-44. doi: 10.1586/erv.11.51. Review."
            }, 
            {
                "PMID": "24063976", 
                "citation": "Verdijk P, Rots NY, van Oijen MG, Oberste MS, Boog CJ, Okayasu H, Sutter RW, Bakker WA. Safety and immunogenicity of inactivated poliovirus vaccine based on Sabin strains with and without aluminum hydroxide: a phase I trial in healthy adults. Vaccine. 2013 Nov 12;31(47):5531-6. doi: 10.1016/j.vaccine.2013.09.021. Epub 2013 Sep 21."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01709071"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Institute of Public Health and the Environment", 
            "investigator_full_name": "Pauline Verdijk", 
            "investigator_title": "Clinical Research Scientist", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Level of virus neutralizing titers in serum", 
            "safety_issue": "No", 
            "time_frame": "28 days after last vaccination"
        }, 
        "source": "National Institute for Public Health and the Environment (RIVM)", 
        "sponsors": {
            "collaborator": {
                "agency": "World Health Organization", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Pauline Verdijk", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}